Key result
Cardiovascular drug trials should eliminate age cutoffs and assess frailty to guide care in older adults.
Answers are grounded in this paper and cite their sources.
We are living in an era of unprecedented aging, with over a billion older people expected to be alive within a few decades. Despite this predictable demographic, drug trials have not kept pace with change and we now have significant evidence-practice gaps. These have arisen due to inappropriate age limits in randomized controlled trials and the near-universal exclusion of frail older people from studies. Suggested solutions include the abolition of age limits in new randomized controlled trials, and the routine measurement of frailty, with a new generation of randomized controlled trials to establish whether treatments remain effective and safe in old age and increasing frailty. We should all have a personal interest in ensuring that drugs used in our old age are truly effective.
No takes yet. Share an insight, caveat, or question.
Richard I. Lindley (2011) conducted a review in Aging and frailty. Drug trials should abolish age limits and routinely measure frailty to address evidence-practice gaps for the over one billion older people expected within decades.
Synapse has enriched 10 related papers. Consider them for comparative context: